AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
lactic acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1533 | 50-21-5 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
|
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | -5.997 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 0.120 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 0.282 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 0.813 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 80.900 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 96.910 | % | High | 1 |
| herg | hERG pIC50 | 4.051 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 3.105 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 3.864 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 83.460 | % | High | 1 |
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK1,JAK2,JAK3,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPKAPK2,MTOR,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK | 51 | |||
| kinase-selectivity-class | ACVR2B,ACVRL1,AXL,BMX,BRAF,CDK9,DYRK1B,EIF2AK3,EPHB4,GRK2,MAP2K6,MAP3K14,MAPK7,PIK3CD,PIK3CG,PRKDC,STK33,SYK,TEK,TGFBR1 | 20 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 0.122 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 0.216 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 99.660 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 0.041 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 88.980 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 1.096 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 97.520 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 98.810 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 803.526 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Joint dislocation | 160.96 | 15.90 | 99 | 15699 | 44483 | 90568166 |
| Seronegative arthritis | 152.87 | 15.90 | 71 | 15727 | 18163 | 90594486 |
| Prescribed underdose | 127.07 | 15.90 | 105 | 15693 | 74914 | 90537735 |
| Joint stiffness | 115.33 | 15.90 | 101 | 15697 | 77941 | 90534708 |
| Wound infection | 101.08 | 15.90 | 108 | 15690 | 106294 | 90506355 |
| Walking aid user | 96.51 | 15.90 | 66 | 15732 | 35440 | 90577209 |
| Retinitis | 94.05 | 15.90 | 67 | 15731 | 38391 | 90574258 |
| Osteoporosis | 93.48 | 15.90 | 99 | 15699 | 96432 | 90516217 |
| Lupus vulgaris | 93.29 | 15.90 | 71 | 15727 | 44988 | 90567661 |
| Visual impairment | 93.06 | 15.90 | 115 | 15683 | 132250 | 90480399 |
| Upper respiratory tract infection | 92.66 | 15.90 | 113 | 15685 | 128205 | 90484444 |
| Laryngitis | 85.83 | 15.90 | 71 | 15727 | 50682 | 90561967 |
| Lupus-like syndrome | 84.00 | 15.90 | 69 | 15729 | 48777 | 90563872 |
| Road traffic accident | 79.68 | 15.90 | 96 | 15702 | 107530 | 90505119 |
| Sciatica | 75.98 | 15.90 | 91 | 15707 | 101291 | 90511358 |
| Type 2 diabetes mellitus | 73.41 | 15.90 | 129 | 15669 | 203115 | 90409534 |
| Psoriasis | 72.79 | 15.90 | 108 | 15690 | 147646 | 90465003 |
| Hypercholesterolaemia | 66.65 | 15.90 | 85 | 15713 | 100807 | 90511842 |
| Joint range of motion decreased | 66.59 | 15.90 | 99 | 15699 | 135544 | 90477105 |
| Anti-cyclic citrullinated peptide antibody | 65.58 | 15.90 | 47 | 15751 | 27174 | 90585475 |
| Broncholithiasis | 64.00 | 15.90 | 14 | 15784 | 293 | 90612356 |
| Lymph node calcification | 60.66 | 15.90 | 14 | 15784 | 376 | 90612273 |
| Liver function test increased | 60.04 | 15.90 | 74 | 15724 | 84781 | 90527868 |
| Adjustment disorder with depressed mood | 54.55 | 15.90 | 58 | 15740 | 56695 | 90555954 |
| Hepatic cirrhosis | 54.45 | 15.90 | 61 | 15737 | 63192 | 90549457 |
| Foot deformity | 53.89 | 15.90 | 59 | 15739 | 59592 | 90553057 |
| Osteoarthritis | 51.90 | 15.90 | 109 | 15689 | 195621 | 90417028 |
| Dislocation of vertebra | 51.68 | 15.90 | 56 | 15742 | 55912 | 90556737 |
| Hip arthroplasty | 51.58 | 15.90 | 65 | 15733 | 76143 | 90536506 |
| Spondylitis | 49.90 | 15.90 | 31 | 15767 | 14147 | 90598502 |
| Disability | 48.97 | 15.90 | 47 | 15751 | 40698 | 90571951 |
| Prescribed overdose | 48.97 | 15.90 | 72 | 15726 | 97553 | 90515096 |
| Spinal fusion surgery | 48.74 | 15.90 | 29 | 15769 | 12254 | 90600395 |
| Lower limb fracture | 47.49 | 15.90 | 66 | 15732 | 84947 | 90527702 |
| Red blood cell sedimentation rate increased | 47.46 | 15.90 | 65 | 15733 | 82530 | 90530119 |
| Knee arthroplasty | 47.10 | 15.90 | 65 | 15733 | 83117 | 90529532 |
| Exostosis | 47.04 | 15.90 | 52 | 15746 | 53082 | 90559567 |
| Bone erosion | 45.41 | 15.90 | 51 | 15747 | 52970 | 90559679 |
| Urticaria | 44.91 | 15.90 | 138 | 15660 | 312596 | 90300053 |
| Pulmonary fibrosis | 43.74 | 15.90 | 72 | 15726 | 107431 | 90505218 |
| Deep vein thrombosis postoperative | 42.61 | 15.90 | 57 | 15741 | 70752 | 90541897 |
| Swollen joint count increased | 40.64 | 15.90 | 71 | 15727 | 111135 | 90501514 |
| Grip strength decreased | 40.39 | 15.90 | 64 | 15734 | 92512 | 90520137 |
| Irritable bowel syndrome | 39.04 | 15.90 | 101 | 15697 | 207347 | 90405302 |
| Drug ineffective | 37.25 | 15.90 | 121 | 15677 | 1384177 | 89228472 |
| Ear infection | 37.23 | 15.90 | 53 | 15745 | 69722 | 90542927 |
| Bronchial wall thickening | 37.19 | 15.90 | 14 | 15784 | 2117 | 90610532 |
| Autoimmune disorder | 36.19 | 15.90 | 55 | 15743 | 76689 | 90535960 |
| Wheezing | 35.98 | 15.90 | 107 | 15691 | 237973 | 90374676 |
| Lichen nitidus | 33.60 | 15.90 | 7 | 15791 | 115 | 90612534 |
| Oedema | 33.13 | 15.90 | 93 | 15705 | 200202 | 90412447 |
| Amnesia | 32.99 | 15.90 | 64 | 15734 | 108441 | 90504208 |
| Mobility decreased | 31.74 | 15.90 | 106 | 15692 | 250628 | 90362021 |
| Injury | 31.05 | 15.90 | 90 | 15708 | 197259 | 90415390 |
| Muscular weakness | 30.38 | 15.90 | 92 | 15706 | 206574 | 90406075 |
| Gait inability | 30.36 | 15.90 | 74 | 15724 | 146382 | 90466267 |
| Oedema peripheral | 29.99 | 15.90 | 106 | 15692 | 257809 | 90354840 |
| Weight decreased | 29.71 | 15.90 | 138 | 15660 | 379772 | 90232877 |
| Delirium | 28.66 | 15.90 | 59 | 15739 | 104300 | 90508349 |
| Weight increased | 28.52 | 15.90 | 146 | 15652 | 417781 | 90194868 |
| Drug-induced liver injury | 28.35 | 15.90 | 54 | 15744 | 90264 | 90522385 |
| Wound | 28.21 | 15.90 | 116 | 15682 | 302864 | 90309785 |
| Tachycardia | 27.85 | 15.90 | 75 | 15723 | 157598 | 90455051 |
| Memory impairment | 27.31 | 15.90 | 86 | 15712 | 197158 | 90415491 |
| Fibromyalgia | 26.81 | 15.90 | 88 | 15710 | 206181 | 90406468 |
| Psoriatic arthropathy | 24.97 | 15.90 | 92 | 15706 | 228243 | 90384406 |
| Hypoaesthesia | 23.72 | 15.90 | 113 | 15685 | 314097 | 90298552 |
| Rheumatic fever | 23.28 | 15.90 | 69 | 15729 | 153052 | 90459597 |
| Liver injury | 22.36 | 15.90 | 73 | 15725 | 170494 | 90442155 |
| Rheumatoid factor positive | 21.20 | 15.90 | 72 | 15726 | 171578 | 90441071 |
| Anaemia | 20.24 | 15.90 | 19 | 15779 | 352783 | 90259866 |
| Muscle injury | 19.16 | 15.90 | 71 | 15727 | 176583 | 90436066 |
| Impaired healing | 18.97 | 15.90 | 86 | 15712 | 234113 | 90378536 |
| Breast cancer stage III | 18.93 | 15.90 | 44 | 15754 | 84403 | 90528246 |
| Sexual abuse | 18.45 | 15.90 | 5 | 15793 | 261 | 90612388 |
| Drug interaction | 18.20 | 15.90 | 13 | 15785 | 276440 | 90336209 |
| C-reactive protein increased | 18.10 | 15.90 | 71 | 15727 | 181318 | 90431331 |
| Product use issue | 17.51 | 15.90 | 19 | 15779 | 329900 | 90282749 |
| Neutropenia | 16.99 | 15.90 | 9 | 15789 | 224895 | 90387754 |
| Soft tissue necrosis | 16.71 | 15.90 | 6 | 15792 | 794 | 90611855 |
| Acute kidney injury | 16.41 | 15.90 | 19 | 15779 | 320368 | 90292281 |
| Contraindicated product administered | 16.38 | 15.90 | 19 | 15779 | 320120 | 90292529 |
| Helicobacter infection | 15.97 | 15.90 | 80 | 15718 | 226770 | 90385879 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Choroiditis | 70.77 | 20.78 | 17 | 3026 | 1358 | 42616934 |
| Endophthalmitis | 59.18 | 20.78 | 19 | 3024 | 4414 | 42613878 |
| Visual acuity reduced | 45.26 | 20.78 | 23 | 3020 | 17527 | 42600765 |
| Intraocular pressure increased | 41.31 | 20.78 | 16 | 3027 | 6417 | 42611875 |
| Completed suicide | 35.68 | 20.78 | 39 | 3004 | 96426 | 42521866 |
| Condition aggravated | 33.99 | 20.78 | 64 | 2979 | 260690 | 42357602 |
| Eye pain | 31.77 | 20.78 | 18 | 3025 | 17012 | 42601280 |
| Psoriasis | 27.91 | 20.78 | 25 | 3018 | 48579 | 42569713 |
| Chondritis | 24.36 | 20.78 | 5 | 3038 | 193 | 42618099 |
| Testicular haemorrhage | 23.06 | 20.78 | 5 | 3038 | 252 | 42618040 |
| Toxicity to various agents | 21.29 | 20.78 | 49 | 2994 | 229087 | 42389205 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Broncholithiasis | 66.93 | 13.98 | 13 | 10536 | 279 | 110578471 |
| Lymph node calcification | 60.79 | 13.98 | 13 | 10536 | 456 | 110578294 |
| Choroiditis | 58.46 | 13.98 | 16 | 10533 | 1599 | 110577151 |
| Psoriasis | 45.13 | 13.98 | 61 | 10488 | 139932 | 110438818 |
| Completed suicide | 42.58 | 13.98 | 80 | 10469 | 242301 | 110336449 |
| Endophthalmitis | 39.27 | 13.98 | 18 | 10531 | 8169 | 110570581 |
| Lichen nitidus | 36.27 | 13.98 | 7 | 10542 | 145 | 110578605 |
| Bronchial wall thickening | 36.06 | 13.98 | 13 | 10536 | 3194 | 110575556 |
| Visual acuity reduced | 30.53 | 13.98 | 25 | 10524 | 32148 | 110546602 |
| Soft tissue necrosis | 30.42 | 13.98 | 9 | 10540 | 1189 | 110577561 |
| Eye pain | 28.10 | 13.98 | 29 | 10520 | 50070 | 110528680 |
| Intraocular pressure increased | 26.12 | 13.98 | 15 | 10534 | 10861 | 110567889 |
| Toxicity to various agents | 25.57 | 13.98 | 102 | 10447 | 480453 | 110098297 |
| Road traffic accident | 24.77 | 13.98 | 40 | 10509 | 107358 | 110471392 |
| Therapeutic reaction time decreased | 23.43 | 13.98 | 11 | 10538 | 5268 | 110573482 |
| Testicular haemorrhage | 21.69 | 13.98 | 5 | 10544 | 248 | 110578502 |
| Sciatica | 20.75 | 13.98 | 34 | 10515 | 92365 | 110486385 |
| Seronegative arthritis | 18.64 | 13.98 | 13 | 10536 | 13164 | 110565586 |
| Sleep disorder due to general medical condition, insomnia type | 17.45 | 13.98 | 34 | 10515 | 105609 | 110473141 |
| Fibromyalgia | 17.03 | 13.98 | 45 | 10504 | 170864 | 110407886 |
| Chondritis | 16.37 | 13.98 | 4 | 10545 | 255 | 110578495 |
| Pruritus | 16.32 | 13.98 | 103 | 10446 | 581457 | 109997293 |
| Post inflammatory pigmentation change | 16.13 | 13.98 | 5 | 10544 | 772 | 110577978 |
| Product distribution issue | 16.10 | 13.98 | 8 | 10541 | 4338 | 110574412 |
| Penile haemorrhage | 15.37 | 13.98 | 5 | 10544 | 903 | 110577847 |
| Product dose omission issue | 15.28 | 13.98 | 66 | 10483 | 321716 | 110257034 |
| Spinal fusion surgery | 15.26 | 13.98 | 10 | 10539 | 9146 | 110569604 |
| Groin infection | 14.56 | 13.98 | 5 | 10544 | 1065 | 110577685 |
| Osteoporosis | 14.33 | 13.98 | 28 | 10521 | 87124 | 110491626 |
| Type 2 diabetes mellitus | 14.08 | 13.98 | 43 | 10506 | 177189 | 110401561 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | G01AD01 | GENITO URINARY SYSTEM AND SEX HORMONES GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS Organic acids |
| CHEBI has role | CHEBI:76971 | <em>Escherichia coli</em> metabolite |
| CHEBI has role | CHEBI:77746 | human metabolite |
| CHEBI has role | CHEBI:35480 | analgesic |
Related Drugs by ATC class:
G01AD Organic acids 2 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Itching of skin | indication | 418363000 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.95 | acidic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 1%;1.8%;0.4% | PHEXX | EVOFEM INC | N208352 | May 22, 2020 | RX | GEL | VAGINAL | 10568855 | March 15, 2033 | PREVENTION OF PREGNANCY |
| 1%;1.8%;0.4% | PHEXX | EVOFEM INC | N208352 | May 22, 2020 | RX | GEL | VAGINAL | 11337989 | March 15, 2033 | PREVENTION OF PREGNANCY |
| 1%;1.8%;0.4% | PHEXX | EVOFEM INC | N208352 | May 22, 2020 | RX | GEL | VAGINAL | 11992472 | March 15, 2033 | PREVENTION OF PREGNANCY |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| 4018704 | VUID |
| N0000147012 | NUI |
| D00111 | KEGG_DRUG |
| 4018704 | VANDF |
| 4020226 | VANDF |
| C0064582 | UMLSCUI |
| CHEBI:28358 | CHEBI |
| LAC | PDB_CHEM_ID |
| CHEMBL1200559 | ChEMBL_ID |
| 612 | PUBCHEM_CID |
| DB04398 | DRUGBANK_ID |
| D019344 | MESH_DESCRIPTOR_UI |
| 114202 | RXNORM |
| 10698 | MMSL |
| 4952 | MMSL |
| 4953 | MMSL |
| 001956 | NDDF |
| 008589 | NDDF |
| 398659005 | SNOMEDCT_US |
| 77370004 | SNOMEDCT_US |
| 3B8D35Y7S4 | UNII |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Wart Removal | HUMAN OTC DRUG LABEL | 2 | 83575-002 | LIQUID | 17 mg | CUTANEOUS | OTC Monograph Drug | 12 sections |